Orphazyme completes enrolment of patients for phase 3 clinical trial in Nieman-Pick type C disease

Orphazyme completes enrolment of patients for phase 3 clinical trial in Nieman-Pick type C disease

Date
May 11, 2017

Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, today announced the completion of enrolment for its lead program within Niemann-Pick type C disease.

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more